NO20044540L - Kimaer pankreas - Google Patents

Kimaer pankreas

Info

Publication number
NO20044540L
NO20044540L NO20044540A NO20044540A NO20044540L NO 20044540 L NO20044540 L NO 20044540L NO 20044540 A NO20044540 A NO 20044540A NO 20044540 A NO20044540 A NO 20044540A NO 20044540 L NO20044540 L NO 20044540L
Authority
NO
Norway
Prior art keywords
recipient
mammalian
pancreatic
tissue
pancreatic tissue
Prior art date
Application number
NO20044540A
Other languages
English (en)
Inventor
Marc R Hammerman
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of NO20044540L publication Critical patent/NO20044540L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Nye fremgangsmåter, vev og preparater for å øke pankreasmassen hos et mottakerpattedyr som omfatter høsting av umodent pankreasvev fra et donorpattedyr og transplantasjon av vevet inn i bukhulen til et mottakerpattedyr under betingelser som gjør at pankreasvevet blir vaskularisert og modnes, slik at det utvikles en fungerende, kimær, endokrin pankreas som danner i det minste insulin i mottakeren. Oppfinnelsen omfatter også umodent pattedyrspankreasvev tilpasset for transplantasjon i bukhulen til et mottakerpattedyr for å øke pankreasmassen hos mottakerpattedyret, så vel som fremgangsmåter og preparater for behandling av pankreasvevet, for immunsupprimering av mottakeren og for kostimulasjonsblokade av mottakeren.
NO20044540A 2002-03-25 2004-10-22 Kimaer pankreas NO20044540L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36718102P 2002-03-25 2002-03-25
PCT/US2003/009091 WO2003083064A2 (en) 2002-03-25 2003-03-24 Chimeric pancreas

Publications (1)

Publication Number Publication Date
NO20044540L true NO20044540L (no) 2004-10-22

Family

ID=28675331

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044540A NO20044540L (no) 2002-03-25 2004-10-22 Kimaer pankreas

Country Status (16)

Country Link
US (2) US7384630B2 (no)
EP (1) EP1487967B1 (no)
JP (1) JP2005521497A (no)
KR (1) KR20040099350A (no)
CN (1) CN1643133A (no)
AT (1) ATE484576T1 (no)
AU (1) AU2003259298B2 (no)
BR (1) BR0308718A (no)
CA (1) CA2477538C (no)
DE (1) DE60334534D1 (no)
EA (1) EA200401244A1 (no)
IL (1) IL164250A0 (no)
MX (1) MXPA04009411A (no)
NO (1) NO20044540L (no)
WO (1) WO2003083064A2 (no)
ZA (1) ZA200406983B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US20090155229A1 (en) * 2004-12-06 2009-06-18 Avner Yayon Chondrocyte-based implant for the delivery of therapeutic agents
EP2514315A3 (en) * 2005-08-24 2012-11-07 Yeda Research and Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
WO2011016423A1 (ja) * 2009-08-02 2011-02-10 学校法人 東京女子医科大学 膵島細胞シート、製造方法及びその利用方法
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804178A (en) * 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
JPH06503001A (ja) * 1991-08-02 1994-04-07 システミックス，インコーポレイティド 免疫不全宿主における原基移植物
EP0867426B1 (de) * 1993-09-07 2002-06-26 Gerhard Dr. Gergely Modifizierte Kristalle einer festen, essbaren, organischen Säure
US5560911A (en) * 1993-10-12 1996-10-01 Oklahoma Medical Research Foundation Method of inhibiting acute complement mediated cytotoxicity with anti-idiotypic antibodies
US5629194A (en) * 1994-10-21 1997-05-13 Diacrin, Inc. Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
JP2003523323A (ja) 1999-12-06 2003-08-05 ザ ジェネラル ホスピタル コーポレーション 膵臓幹細胞および移植におけるその使用
US20020168371A1 (en) * 2000-05-18 2002-11-14 Michel Awwad Process for reducing antibody response against xenografts
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism

Also Published As

Publication number Publication date
BR0308718A (pt) 2005-01-04
US20030198628A1 (en) 2003-10-23
EP1487967A4 (en) 2005-05-11
JP2005521497A (ja) 2005-07-21
EA200401244A1 (ru) 2005-02-24
KR20040099350A (ko) 2004-11-26
WO2003083064A2 (en) 2003-10-09
EP1487967B1 (en) 2010-10-13
CA2477538A1 (en) 2003-10-09
CA2477538C (en) 2008-01-29
AU2003259298A1 (en) 2003-10-13
ATE484576T1 (de) 2010-10-15
ZA200406983B (en) 2005-09-22
AU2003259298B2 (en) 2006-08-31
IL164250A0 (en) 2005-12-18
CN1643133A (zh) 2005-07-20
US7384630B2 (en) 2008-06-10
EP1487967A2 (en) 2004-12-22
DE60334534D1 (de) 2010-11-25
MXPA04009411A (es) 2005-01-25
US20080318202A1 (en) 2008-12-25
WO2003083064A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
MX2009014273A (es) Metodos y composiciones para expansion e implantacion optimizadas de celulas madre mesenquimales.
ATE382681T1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
WO2010022395A3 (en) Methods of reprogramming cells
WO2006042238A3 (en) Methods of storing tissue matrices
TW200503794A (en) Treatment of tissue with undifferentiated mesenchymal cells
ATE484576T1 (de) Chimäre bauchspeicheldrüse
WO2005086860A3 (en) Methods for generating insulin-producing cells
WO2009050742A8 (en) Use of microvesicles (mvs) for preparing a medicament having adjuvant activity on endothelial cell transplantation, particularly in the treatment of diabetes by pancreatic islet transplantation, and related method
EP1910519A4 (en) IMMUNOPHÄNOTYP AND IMMUNOGENICITY OF HUMAN CELLS FROM FAT TISSUE
IL190693A (en) Substance damage suppressants are implanted after islet transplantation, containing and utilizing antibodies that detect il-6 receptor.
BRPI0519783A2 (pt) composições imunogênicas de pvc2 e métodos de produzir tais composições
DK1248640T3 (da) Xenotransplantation af svineöer og deres fremstilling
MX2021011709A (es) Celulas, tejidos y organos personalizados para trasplante de un donante humanizado, adaptado, designado libre de patogenos (no humano) y metodos y productos relacionados con estos.
WO2006073890A3 (en) Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
WO2006107850A3 (en) Preventing rejection of transplanted tissue using regulatory t cells
GB2397825B (en) Method of producing human beta cell lines
TW200833836A (en) An improved method of cultivating the Cordyceps Militaris by adding sugar cane fiber
JP2005521497A5 (no)
Jang et al. Genome editing for engineering stem cell-derived pancreatic β cells: recent trends and future perspectives
MX2021009855A (es) Roedores que tienen canales de sodio modificados geneticamente y metodos de uso de los mismos.
SE0401807D0 (sv) Förfaranden och kompositioner för nytillväxt av kryopreserverade tallembryon
PL1664307T3 (pl) Nowy, specyficzny dla bielma promotor roślinny dla roślin uprawnych
WO2006079107A3 (en) Transplantation compositions and methods for treating diabetes
Kim et al. Susceptibility of porcine keratocytes to immune-mediated damage in xeno-related rejection
UA39614A (uk) Спосіб корекції функціонального стану міокарда у лабораторних тварин пізнього онтогенезу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application